Halozyme Therapeutics Inc.
Price
Key statistics
- Forward rate
- $0.00
- Yield
- 0.00%
- Payout ratio
- 0.00%
- Frequency
- Unknown
Halozyme Therapeutics Inc. is a biopharmaceutical technology company focused on drug delivery solutions and specialty medicines. Its core platform, ENHANZE, uses the proprietary enzyme rHuPH20 to help enable subcutaneous delivery of injectable therapies and fluids, supporting more convenient administration and improved patient comfort. The company also develops, manufactures, and commercializes drug-device combination products with advanced auto-injector technology for use in areas such as oncology and other specialty therapeutic settings. In addition to its platform business, Halozyme Therapeutics Inc. markets proprietary products including Hylenex and XYOSTED, and works with pharmaceutical partners to support a range of commercial and development-stage programs. Headquartered in San Diego, California, Halozyme Therapeutics Inc. plays a specialized role in the biopharmaceutical market by providing technologies that help improve how existing medicines are delivered and used.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
- Employees
- 423
- Headquarters
- San Diego, CA, United States
- Website
- halozyme.com